Corvus Pharmaceuticals (CRVS) Retained Earnings (2015 - 2026)

Corvus Pharmaceuticals' Retained Earnings history runs 12 years deep, the most recent figure standing at -$426.0 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 33870.1% year-over-year to -$426.0 million; the TTM figure through Mar 2026 stood at -$426.0 million (down 33870.1% YoY), while the FY2025 annual figure was -$412.3 million, down 195.69% from the prior year.
• Retained Earnings for Q1 2026 stood at -$426.0 million, down from -$412.3 million in the prior quarter.
• The five-year high for Retained Earnings was $430.9 million in Q4 2024, with the low at -$426.0 million in Q1 2026.
• The 5-year median for Retained Earnings is -$1.3 million (2024), against an average of -$138.4 million.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings tumbled 331063.86% in 2022, then jumped 44656.26% in 2024.
• Corvus Pharmaceuticals' Retained Earnings stood at -$563000.0 in 2022, then slumped by 71.76% to -$967000.0 in 2023, then surged by 44656.26% to $430.9 million in 2024, then sank by 195.69% to -$412.3 million in 2025, then decreased by 3.32% to -$426.0 million in 2026.
• Business Quant data shows CRVS's Retained Earnings at -$426.0 million in Q1 2026, -$412.3 million in Q4 2025, and -$1.1 million in Q3 2025.